A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma-Reference-Cited by-同舟云学术

A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma

Published:2017-06-22 Issue:20 Volume:123 Page:3977-3985
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Chan Stephen L.¹²³^ORCID,Yeo Winnie¹²,Mo Frankie¹²,Chan Anthony W.H.¹⁴^ORCID,Koh Jane²,Li Leung²,Hui Edwin P.¹²,Chong Charing C.N.⁵,Lai Paul B.S⁵,Mok Tony S.K.¹²,Yu Simon C.H.⁶

Affiliation:

1. State Key Laboratory of Oncology in South China; Hong Kong

2. Sir YK Pao Center for Cancer; Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong; Hong Kong

3. Institute of Digestive Disease; The Chinese University of Hong Kong; Hong Kong

4. Department of Anatomical and Cellular Pathology; The Chinese University of Hong Kong; Hong Kong

5. Department of Surgery; The Chinese University of Hong Kong; Hong Kong

6. Department of Imaging and Interventional Radiology; The Chinese University of Hong Kong; Hong Kong

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30825/fullpdf

Reference31 articles.

1. The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma;Yang;Cancer Res.,2004

2. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level;Li;World J Gastroenterol.,2004

3. TACE and sorafenib: a good marriage?;Abou-Alfa;J Clin Oncol.,2011

4. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial;Lencioni;J Hepatol.,2016

5. TACE 2: a randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC) [abstract];Meyer;J Clin Oncol.,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

2. Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives;Discover Oncology;2024-07-03

3. Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review;Oncology Research;2024

4. Function and biomedical implications of exosomal microRNAs delivered by parenchymal and nonparenchymal cells in hepatocellular carcinoma;World Journal of Gastroenterology;2023-10-21

5. The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms;Frontiers in Immunology;2023-05-31